NCT03193853 2023-08-07
TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
Baylor Research Institute
Phase 2 Completed
Clinical Trials
5 trialsNCT02049957 2023-02-08
Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
Calithera Biosciences, Inc
Phase 2 Completed
NCT02756364 2023-02-08
Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy
Calithera Biosciences, Inc
Phase 2 Completed
NCT02988986 2021-09-22
ANETT
The Methodist Hospital Research Institute
Phase 2 Completed
NCT02619669 2020-03-12
Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
Dartmouth-Hitchcock Medical Center
Phase 1 Withdrawn